Having already obtained approval from the US Food and Drug Administration for their partnered Selarsdi (ustekinumab-aekn) rival to Stelara earlier this year, partners Teva and Alvotech have now obtained a further nod from the agency that authorizes a further presentation for the biosimilar as well as expanding its label to cover adults with Crohn’s disease and ulcerative colitis.
Teva And Alvotech Add Indications For US Stelara Rival
Selarsdi Version Of Ustekinumab Approved For Crohn’s Disease And Ulcerative Colitis
Alvotech and US marketing partner Teva have celebrated a further approval for their Selarsdi ustekinumab biosimilar rival to Stelara that encompasses a new presentation as well as a label expansion to include adults with Crohn’s disease and ulcerative colitis.
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.